Astrazeneca (AZN) Gains from Investment Securities (2014 - 2026)

Astrazeneca (AZN) posted quarterly Gains from Investment Securities of -$123.0 million for Q3 2014.

Astrazeneca (AZN) Gains from Investment Securities (2014 - 2026) Analysis & Trends

Astrazeneca's Gains from Investment Securities history runs 1 years deep, the most recent figure standing at -$123.0 million for Q3 2014.

In Q3 2014, Gains from Investment Securities changed N/A year-over-year to -$123.0 million; the TTM figure through Sep 2014 stood at -$119.0 million (changed N/A YoY), while the FY2016 annual figure was -$1.3 billion, down 35.38% from the prior year.
Gains from Investment Securities for Q3 2014 stood at -$123.0 million.
The five-year high for Gains from Investment Securities was -$123.0 million in Q3 2014, with the low at -$123.0 million in Q3 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn

Download Data